Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ertapenem Sodium

FDA-approved product (injectable, intramuscular, intravenous), marketed as Ertapenem Sodium, Invanz.

Registered studies
50+
Lab records
186
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ertapenem Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial pneumonia
  • Community-Acquired Infections
  • Gram-negative bacterial infections
  • Infection
  • Osteomyelitis
  • Staphylococcal skin infections
  • Streptococcal infection
  • Surgical Wound Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH03

Repurposing investigation

Ertapenem Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • K. pneumoniae99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 141 of 186 lab records
Open Ertapenem Sodium in ChEMBL Registered studies below
Show the latest 150 of 186 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ertapenem Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments

    NCT01703299 · start 2012-10

    Registered record
    Registry ID
    NCT01703299
    Conditions
    Carbapenem-induced Resistance
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-03
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-induced Resistance
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics of Carbapenem Antibiotics in Obese Patients.

    NCT01407965 · start 2012-04

    Registered record
    Registry ID
    NCT01407965
    Conditions
    Obesity
    Interventions
    microdialysis catheter; microdialysis catheter
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-04
    Completion
    2015-07
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    Interventionmicrodialysis catheter; microdialysis catheter
    PhasePhase 4
    Registry statusCompleted

  • Antibiotics Versus Surgery in Acute Appendicitis

    NCT01421901 · start 2011-08

    Registered record
    Registry ID
    NCT01421901
    Conditions
    Acute Appendicitis Without Peritonitis
    Interventions
    Ertapenem; appendectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-08
    Completion
    2015-06
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis Without Peritonitis
    InterventionErtapenem; appendectomy
    PhasePhase 4
    Registry statusUnknown

  • A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

    NCT01886053 · start 2011-04

    Registered record
    Registry ID
    NCT01886053
    Conditions
    Community Acquired Pneumonia
    Interventions
    Faropenem（high dose group）; Faropenem（low-dose group); Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-04
    Completion
    2012-07
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia
    InterventionFaropenem（high dose group）; Faropenem（low-dose group); Ertapenem
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion

    NCT01148771 · start 2010-08

    Registered record
    Registry ID
    NCT01148771
    Conditions
    Healthy
    Interventions
    ertapenem; ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionertapenem; ertapenem
    PhasePhase 4
    Registry statusCompleted

  • Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

    NCT01069900 · start 2010-07-21

    Registered record
    Registry ID
    NCT01069900
    Conditions
    Intraabdominal Infections
    Interventions
    Moxifloxacin (Avelox, BAY12-8039); Ertapenem; Amoxicillin/Clavulanate; Moxifloxacin placebo; Ertapenem placebo; Amoxicillin/Clavulanate placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07-21
    Completion
    2015-01-21
    Enrolment
    458

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntraabdominal Infections
    InterventionMoxifloxacin (Avelox, BAY12-8039); Ertapenem; Amoxicillin/Clavulanate; Moxifloxacin placebo +2 more
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics Ertapenem Burns

    NCT01497990 · start 2010-01

    Registered record
    Registry ID
    NCT01497990
    Conditions
    Burn Patients
    Interventions
    Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-01
    Completion
    2011-09
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurn Patients
    InterventionErtapenem
    PhasePhase 4
    Registry statusCompleted

  • Appendicectomy Versus Antibiotics in the Treatment of Acute Uncomplicated Appendicitis

    NCT01022567 · start 2009-11

    Registered record
    Registry ID
    NCT01022567
    Conditions
    Acute Appendicitis
    Interventions
    Appendicectomy; Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2009-11
    Completion
    2025-12
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis
    InterventionAppendicectomy; Ertapenem
    PhaseNot applicable
    Registry statusUnknown

  • Pharmacokinetic Interactions in Combination Treatment of Valproic Acid and Ertapenem in Normal Subjects

    NCT01073059 · start 2009-08

    Registered record
    Registry ID
    NCT01073059
    Conditions
    Healthy
    Interventions
    Valproic acid and Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    Not recorded
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionValproic acid and Ertapenem
    PhasePhase 1
    Registry statusCompleted

  • The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan

    NCT01725841 · start 2009-04

    Registered record
    Registry ID
    NCT01725841
    Conditions
    Enterobacteriaceae Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterobacteriaceae Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)

    NCT01014013 · start 2008-04

    Registered record
    Registry ID
    NCT01014013
    Conditions
    Urinary Tract Infection
    Interventions
    ertapenem sodium (MK0826); Comparator: ceftriaxone sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-04
    Completion
    2009-02
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection
    Interventionertapenem sodium (MK0826); Comparator: ceftriaxone sodium
    PhasePhase 3
    Registry statusCompleted

  • Penetration of Ertapenem Into Bone

    NCT00392028 · start 2006-11

    Registered record
    Registry ID
    NCT00392028
    Conditions
    Amputation
    Interventions
    ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2006-11
    Completion
    2007-07
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmputation
    Interventionertapenem
    PhaseNot applicable
    Registry statusWithdrawn

  • To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)

    NCT00398099 · start 2005-07

    Registered record
    Registry ID
    NCT00398099
    Conditions
    Infection; Pneumonia; Urinary Tract Infection
    Interventions
    MK0826, ertapenem sodium / Duration of Treatment: 14 Days
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-07
    Completion
    2006-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Pneumonia; Urinary Tract Infection
    InterventionMK0826, ertapenem sodium / Duration of Treatment: 14 Days
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)

    NCT00379951 · start 2005-06

    Registered record
    Registry ID
    NCT00379951
    Conditions
    Urinary Tract Infection
    Interventions
    ertapenem sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-06
    Completion
    2006-05
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection
    Interventionertapenem sodium
    PhasePhase 3
    Registry statusCompleted

  • To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)

    NCT00397956 · start 2004-09

    Registered record
    Registry ID
    NCT00397956
    Conditions
    Sepsis
    Interventions
    MK0826, ertapenem sodium / Duration of Treatment: 14 Days
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-09
    Completion
    2005-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionMK0826, ertapenem sodium / Duration of Treatment: 14 Days
    PhasePhase 3
    Registry statusCompleted